Elucidating the Mechanism of Novel Dengue Antivirals
Elucidating the Mechanism of Novel Dengue Antivirals
批准号:
7897283
负责人:
Stanley J Watowich
金额:
$18.52万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-08-17 至 2010-07-31
关键词:
AcidsAddressAntiviral AgentsBiological AssayBlood ClotBlood coagulationCategoriesCell Culture TechniquesCellsClassificationClinicalComputersCulicidaeCultured CellsDatabasesDengueDengue VirusDevelopmentEnsureFlavivirusFlavivirus InfectionsFoundationsFutureHealthHealth systemHepatitis C virusIn VitroIndividualKineticsLabelLeadMeasuresMolecular WeightPeptide HydrolasesPermeabilityPhaseProtease InhibitorPublic HealthRecombinantsReporterResearch PersonnelRibavirinScreening procedureSerine ProteaseSiteSolidSpecificityStructureTestingTherapeuticTrypsinVaccinesViral Hemorrhagic FeversViral PhysiologyVirusVirus DiseasesWest Nile virusWorld Health OrganizationYellow Feverbasechymotrypsincombatcomputer studiescytotoxiccytotoxicitydengue virus NS3in vitro Assayin vitro activityindexinginhibitor/antagonistnovelpathogenprogramsresearch studysmall moleculesuccessvirtual
中文摘要
描述(由申请人提供):目前尚无抗病毒药物或疫苗可对抗登革病毒(DENV)感染。这是一个严重的失败,因为DENV是公认的A类生物恐怖分子。此外,每年DENV导致约150万登革热临床病例,其中50万感染者发展为严重出血热。为了解决缺乏治疗方法来对抗这种高度优先和广泛传播的病原体,我们使用“虚拟筛选”来发现假定的DEN2V NS3蛋白酶抑制剂。这种计算密集的方法系统地检查了一个小分子数据库,以确定可能与DEN2V NS3蛋白酶的催化或P1位点相互作用的化合物。我们的计算研究预测,大约有170个低分子量化合物将作为DEN2V NS3蛋白酶抑制剂发挥作用。使用计算机推荐的一小部分抑制剂和重组DEN2V NS3蛋白酶进行初步的体外试验。值得注意的是,大多数被测试的化合物降低了DEN2V NS3蛋白酶的活性。在初步的细胞培养实验中进一步检测了两个化合物;两个化合物都表现出了对抗DEN2V攻击的抗病毒活性。这些化合物具有亚微摩尔的EC50值,没有明显的细胞毒性,选择性指数>;150,对胰酶蛋白分解活性没有影响。鉴于我们在从计算机预测的抑制剂中识别有前景的登革热抗病毒线索方面取得的初步成功,我们假设,通过彻底分析我们计算研究推荐的整套化合物,将发现更多新的抗病毒线索。为了验证这一假设,我们将完成体外DEN2V NS3蛋白酶检测,以确定每个计算机推荐的化合物的Ki和抑制机制(特定目标1)。KI值低的化合物将在培养细胞中进行抗病毒活性测试(特定目标2),并使用一种新的基于细胞的NS3蛋白酶报告试验(特定目标3)验证其抗病毒机制。新发现的抑制剂的特异性将通过相关的丝氨酸蛋白酶、胰凝乳酶和凝血试验进一步测试。由于出血性并发症通常伴随着DENV感染,凝血试验是谨慎的,以确保登革热蛋白水解酶抑制剂不会干扰凝血级联反应(具体目标4)。该项目的成功完成将确定和表征新的抗病毒药物,为进一步开发用于治疗登革热病毒感染的药物奠定基础。此外,确定这些先导抗病毒药物的机制基础和特异性将为未来基于结构的抗病毒优化研究提供坚实的基础,以生产出对相关黄病毒有效的治疗药物,包括西尼罗河病毒、黄热病和丙型肝炎病毒。
英文摘要
DESCRIPTION (provided by applicant): No antivirals or vaccines exist to combat dengue virus (DENV) infection. This is a serious failing since DENV is a recognized Category A bioterrorist agent. In addition, annually DENV causes about1.5 million clinical cases of dengue fever with >500,000 infected individuals developing severe hemorrhagic fever. To address the lack of therapeutics to combat this high-priority and widespread pathogen, we used "virtual screening" to discover putative DEN2V NS3 protease inhibitors. This computationally intensive approach systematically examined a database of small molecules to identify compounds that might interact with either the catalytic or P1 sites of DEN2V NS3 protease. Our computational studies predicted approximately 170 low molecular weight compounds would function as DEN2V NS3 protease inhibitors. Preliminary in vitro assays were done using a small subset of computer-recommended inhibitors and recombinant DEN2V NS3 protease. Significantly, the majority of tested compounds reduced DEN2V NS3 protease activity. Two compounds were further examined in preliminary cell culture experiments; both compounds demonstrated antiviral activity against DEN2V challenge. These compounds had sub-micromolar EC50 values, no apparent cytotoxicity, selectivity indices >150, and no impact on trypsin proteolytic activity. Given our initial success at identifying promising dengue antiviral leads from computer-predicted inhibitors, we hypothesize that additional novel antiviral leads will be found by thoroughly analyzing the entire set of compounds recommended by our computational studies. To test this hypothesis, we will complete in vitro DEN2V NS3 protease assays to determine the Ki and inhibition mechanism of each computer-recommended compound (Specific Aim 1). Compounds with low Ki values will be tested for antiviral activity in cultured cells (Specific Aim 2), and their antiviral mechanism validated using a novel cell-based NS3 protease reporter assay (Specific Aim 3). The specificity of newly discovered inhibitors will be further tested using related serine proteases trypsin and chymotrypsin, and blood-clotting assays. Since hemorrhagic complications often accompany DENV infection, the blood-clotting assay is prudent to ensure dengue protease inhibitors do not interfere with the blood coagulation cascade (Specific Aim 4). Successful completion of this project will identify and characterize new antiviral leads for further development as therapeutics for dengue virus infection. In addition, determining the mechanistic basis and specificity of these lead antivirals will provide a solid foundation for future structure-based antiviral optimization studies to produce therapeutics effective against related flaviviruses, including West Nile, Yellow Fever, and Hepatitis C viruses.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1021/bi801034f
发表时间:
2008-11-11
期刊:
Biochemistry
影响因子:
2.9
作者:
[Tomlinson SM, Watowich SJ]
通讯作者:
Watowich SJ
Development of NNMT inhibitors as novel interventions to activate quiescent muscle stem cells and improve age-related muscle degeneration
-
批准号:9905476
-
项目类别:
-
资助金额:$19.75万
-
财政年份:2019
-
负责人:Stanley J Watowich
-
依托单位:
Elucidating the Mechanism of Novel Dengue Antivirals
-
批准号:7197754
-
项目类别:
-
资助金额:$22.65万
-
财政年份:2007
-
负责人:Stanley J Watowich
-
依托单位:
Elucidating the Mechanism of Novel Dengue Antivirals
-
批准号:7484924
-
项目类别:
-
资助金额:$18.52万
-
财政年份:2007
-
负责人:Stanley J Watowich
-
依托单位:
VENEZUELAN EQUINE ENCEPHALOMYELITIS VIRUS
-
批准号:7598584
-
项目类别:
-
资助金额:$0.81万
-
财政年份:2006
-
负责人:Stanley J Watowich
-
依托单位:
VENEZUELAN EQUINE ENCEPHALOMYELITIS VIRUS
-
批准号:7357776
-
项目类别:
-
资助金额:$0.75万
-
财政年份:2005
-
负责人:Stanley J Watowich
-
依托单位:
STRUCTURE OF VEE VIRUS NSP2 PROTEASE: BIOLOGICAL WARFARE
-
批准号:6978230
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2004
-
负责人:Stanley J Watowich
-
依托单位:
VENEZUELAN EQUINE ENCEPHALOMYELITIS VIRUS
-
批准号:7181080
-
项目类别:
-
资助金额:$1.85万
-
财政年份:2004
-
负责人:Stanley J Watowich
-
依托单位:
VENEZUELAN EQUINE ENCEPHALOMYELITIS VIRUS
-
批准号:6980387
-
项目类别:
-
资助金额:$1.08万
-
财政年份:2003
-
负责人:Stanley J Watowich
-
依托单位:
Novel Countermeasures to Hemorrhagic Fever Viruses
-
批准号:6651648
-
项目类别:
-
资助金额:$22.35万
-
财政年份:2002
-
负责人:Stanley J Watowich
-
依托单位:
Novel Countermeasures to Hemorrhagic Fever Viruses
-
批准号:6562363
-
项目类别:
-
资助金额:$22.35万
-
财政年份:2002
-
负责人:Stanley J Watowich
-
依托单位:
INTERACTIONS STABILIZING HEMAGGLUTININ-RECEPTOR BINDING
-
批准号:3030451
-
项目类别:
-
资助金额:$3.05万
-
财政年份:1991
-
负责人:Stanley J Watowich
-
依托单位:
STRUCTURE AND ENERGETICS OF SICKLE HEMOGLOBIN AGGREGATES
-
批准号:3050678
-
项目类别:
-
资助金额:$2.93万
-
财政年份:1989
-
负责人:Stanley J Watowich
-
依托单位:
STRUCTURE AND ENERGETICS OF SICKLE HEMOGLOBIN AGGREGATES
-
批准号:3050677
-
项目类别:
-
资助金额:$2.5万
-
财政年份:1988
-
负责人:Stanley J Watowich
-
依托单位:
海外基金